Serum cytokeratin 19 fragment in advanced lung cancer: could we eventually have a serum tumor marker?
| Title: | Serum cytokeratin 19 fragment in advanced lung cancer: could we eventually have a serum tumor marker? |
|---|---|
| Authors: | Bastawisy AE; Medical Oncology and Haematology, National Cancer Institute, Cairo University, Cairo 11796, Egypt.; Azzouny ME; Clinical Pathology, Benha University, Benha 13511, Egypt.; Mohammed G; Clinical Pathology, Benha University, Benha 13511, Egypt.; Allah AA; Clinical Pathology, Benha University, Benha 13511, Egypt.; Behiry E; Clinical Pathology, Benha University, Benha 13511, Egypt. |
| Source: | Ecancermedicalscience [Ecancermedicalscience] 2014 Jan 30; Vol. 8, pp. 394. Date of Electronic Publication: 2014 Jan 30 (Print Publication: 2014). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: ecancer Country of Publication: England NLM ID: 101392236 Publication Model: eCollection Cited Medium: Print ISSN: 1754-6605 (Print) Linking ISSN: 17546605 NLM ISO Abbreviation: Ecancermedicalscience Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Publication: Bristol, UK : ecancer; Original Publication: Bristol, UK : Cancer Intelligence |
| Abstract: | Introduction: Lung cancer is one of the most lethal malignancies; however, no serum marker has been routinely recommended until now.; Methods: THIS IS A PROSPECTIVE CASE CONTROL STUDY INCLUDING TWO GROUPS OF PATIENTS: Group I-patients with advanced lung cancer and Group II-patients with benign lung disease as control. Serum cytokeratin 19 (CK19) fragment levels were measured at baseline by real-time polymerase chain reaction before first-line chemotherapy. The CK19 cut-off taken was 15-cycle threshold. The primary end point was the comparison of high CK19 in cases and controls. The secondary end point was the correlation between high CK19 and progressive disease (PD), progression-free survival, and overall survival (OS) in advanced lung cancer patients.; Results: A total of 30 patients with advanced lung cancer (16 non-small and 14 small cell lung cancer) and 15 patients with benign lung disease were included and followed up during the period from October 2008 to October 2011 with median follow-up of one and half years. High CK19 was found in 90% of lung cancer cases as compared with 7% in controls (p < 0.001). High CK19 was found in all cases showing PD (p = 0.04). One-year OS in high CK was 61% as compared with 33% in normal CK (p = 0.1).; Conclusion: Serum CK19 fragment is a potential diagnostic and prognostic marker for advanced lung cancer. |
| References: | Chest. 1995 Jul;108(1):163-9. (PMID: 7541742); Anticancer Res. 1996 Jul-Aug;16(4B):2161-8. (PMID: 8694537); Biomarkers. 2010 Nov;15(7):594-601. (PMID: 20649505); J Clin Oncol. 1995 Nov;13(11):2769-75. (PMID: 7595737); Ann Thorac Surg. 2007 Jan;83(1):216-21. (PMID: 17184666); Eur Respir J. 1997 Mar;10(3):603-9. (PMID: 9072992); Khirurgiia (Sofiia). 2008;(3):18-20. (PMID: 20058724); J Thorac Oncol. 2006 Sep;1(7):752-5. (PMID: 17409954); Eur J Cancer. 1997 Mar;33(3):385-91. (PMID: 9155521); Lung Cancer. 2007 Apr;56(1):105-14. (PMID: 17166620); Zhonghua Yi Xue Za Zhi. 2010 Jul 27;90(28):1958-62. (PMID: 20979858); CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855); Br J Cancer. 1997;75(3):448-50. (PMID: 9020496); Pol Arch Med Wewn. 2004 Jun;111(6):659-65. (PMID: 15508787) |
| Contributed Indexing: | Keywords: cytokeratin 19 fragment; lung cancer |
| Entry Date(s): | Date Created: 20140226 Date Completed: 20140225 Latest Revision: 20241006 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC3907401 |
| DOI: | 10.3332/ecancer.2014.394 |
| PMID: | 24567753 |
| Database: | MEDLINE |
Journal Article